EpiPens typically have a shelf life of 20 months, according to the FDA, which said This kind of’s allowing the additional four months after reviewing stability data provided by Mylan. The move comes as parents of children with allergies are finding EpiPens hard to come by in pharmacies as they stock up for back-to-school season.
“We are doing everything we can to help mitigate shortages of these products, especially ahead of the back-to-school season,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation along with also Research, said in a statement. “We’re hopeful This kind of action will ensure patients have access to This kind of important medication along with also provide additional peace-of-mind to parents as the agency works with the producer to raise supply.”
Last week, the agency approved the first generic competitor to the EpiPen, coming from Teva Pharmaceuticals, although This kind of’s not likely to reach the market for a few months.